Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05155709 · ClinicalTrials.gov registry record · Phase 1
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05155709 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT05155709, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
A study of siremadlin in combination with venetoclax plus azacitidine in adult participants with AML who are ineligible for chemotherapy. The primary purpose of this study was to assess whether siremadlin in combination with venetoclax plus azacitidine can enhance the clinical response in unfit AML participants without unacceptable levels of treatment-emergent toxicities.
Interventions
- DRUG venetoclax
- DRUG azacitidine
- DRUG siremadlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2024-04-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05155709
The ClinicalTrials.gov registry entry for NCT05155709 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which venetoclax is the first listed.
NCT05155709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05155709 about?
NCT05155709 is a clinical study titled "A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.". A study of siremadlin in combination with venetoclax plus azacitidine in adult participants with AML who are ineligible for chemotherapy. The primary purpose of this study was to assess whether siremadlin in combination with venetoclax plus azacitidine can enhance the clinical response in unfit AML...
What is the current status of trial NCT05155709?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-05-17. Estimated completion is 2024-04-17.
What interventions are being tested in trial NCT05155709?
The interventions under investigation include: venetoclax (DRUG), azacitidine (DRUG), siremadlin (DRUG).
Who is sponsoring clinical trial NCT05155709?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.